ACE Technology Guidances

ACE Technology Guidances communicate recommendations from the MOH Drug Advisory Committee or the MOH Medical Technology Advisory Committee on the funding status and appropriate use of drugs, vaccines or medical technologies that have been evaluated by ACE. The guidances also include the Committee’s rationale for the funding recommendations, and key clinical and economic evidence which informed their deliberations. Plain English Summaries (PES) to explain ACE Technology Guidances are available for patients and the public.

Published on 02 Sep 2019
Last Updated on 02 Sep 2019
A- A+
Guidance Recommendations
The Ministry of Health's Drug Advisory Committee has recommended:
  • celecoxib 200 mg capsule; and
  • etoricoxib 60 mg, 90 mg and 120 mg tablets
for treating pain in line with their registered indications in Singapore.

For patients with renal impairment or who have an increased risk of cardiovascular events, clinicians should consider prescribing COX-2 inhibitors at the lowest effective daily dose for the shortest duration possible.

Subsidy status
Celecoxib 200 mg capsule and etoricoxib 60 mg, 90 mg and 120 mg tablets are recommended for inclusion on the MOH Standard Drug List (SDL) for the abovementioned indication.

Oral COX-2 inhibitors for pain (2 Sep 2019) Oral COX-2 inhibitors for pain Plain English Summary (2 Sep 2019)